Journals / Medicine Science / 2020 / Cilt: 9 - Sayı: 4

Evaluation of manganese superoxide dismutase and thioredoxin2 levels in asbestos-induced pleural mesothelioma

Pages
912–916
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The study presents basic findings for the clinical meaning of mentioned biochemical parameters in mesothelioma patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Asbestos is a mineral known as human carcinogenic material.
📊
Key Findings & Data:ROS contributes to the development of pulmonary-toxicity induced asbestos.We aimed to determine the levels of important mitochondrial substances such as manganese superoxide dismutase (MnSOD) and Thioredoxin (Trx2) in asbestosis and mesothelioma patients.
💡
Conclusion & Impact:The study presents basic findings for the clinical meaning of mentioned biochemical parameters in mesothelioma patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Asbestos is a mineral known as human carcinogenic material. Exposure to asbestos both in an occupational and environmental way causes asbestosis and mesothelioma. ROS contributes to the development of pulmonary-toxicity induced asbestos.We aimed to determine the levels of important mitochondrial substances such as manganese superoxide dismutase (MnSOD) and Thioredoxin (Trx2) in asbestosis and mesothelioma patients. The study was performed with the patients admitted to outpatient clinics of Chest Diseases and Thoracic Surgery, at Medicine Faculty, Bozok University. Group 1 (healthy control group, n=27): Consisting of healthy individuals (54.18±9.89 years old), Group 2 (patients group, n=34): Evaluation of clinical, pathological and radiological analysis, patients who defined as mesothelioma and/or pleural plaques and asbestosis (60.24±15.24 years old). Patients, who were not biopsied or not available for biopsy due to comorbid diseases, were not included in the study.Biochemical analysis was done in Selcuk University Medicine Faculty Research Laboratories.Serum Trx2 and MnSOD levels were determined by the Elisa method. The results of Trx2 were calculated as pg/µg protein. MnSOD samples were determined as ng/µg protein. MnSOD and Trx2 levels in the patients’ group were statistically lower than the levels of the healthy group (p=0.000, p=0.048), respectively.Trx2 levels were 1.74±0.33 pg/µg protein in a healthy group whereas were 0.89±0.10 pg/µg protein in asbestosis and mesothelioma group. Serum MnSOD levels were 1.38±0.24 and 0.29±0.11 ng/µg protein in healthy and patients’ groups, respectively.These significant changes in malignant mesothelioma patients reflect the impairment of the oxidant-antioxidant balance system. The study presents basic findings for the clinical meaning of mentioned biochemical parameters in mesothelioma patients.

🔖

Cite This Article

SİVRİKAYA, A., METİN, B., MENEVSE, E., İNTEPE, Y. S., GÖÇMEN, A. Y. (2020). Evaluation of manganese superoxide dismutase and thioredoxin2 levels in asbestos-induced pleural mesothelioma. Medicine Science, Cilt: 9 - Sayı: 4, 912–916. https://ajindex.com/articles/276772

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Gibbs G, Berry G. Mesothelioma and asbestos. Regul Toxicol Pharmacol. 2008;52;223-31
  2. Turkey asbestos control strategic plan final report. Turk Thorac J. 2015;16:27–52
  3. Liu G, Cheresh P, Kamp DW. Molecular basis of asbestos-induced lung disease.Annu Rev Pathol. 2013;24:161-87
  4. Zalewska-Ziob M, Adamek B, Kasperczyk J, et al. Activity of antioxidant enzymes in the tumor and adjacent noncancerous tissues of non-small-cell lung cancer. Oxid Med Cell Longev. 2019;31:2901840
  5. Kamp DW, Graceffa P, Pryor WA, et al. The role of free radicals in asbestosinduced diseases. Free Radic Biol Med.1999;12:293–315
  6. Huang SXL, Jaurand M-C, Kamp DW, et al. Role of mutagenicity in asbestos fiber–induced carcinogenicity and other diseases. J Toxicol Environ Health. 2011;14:179–245
  7. Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. Mutat Res. 2004;567:1-61
  8. Oberley LW. Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother. 2005;59:143-8
  9. Azadmanesh J, Borgstahl EO. A review of the catalytic mechanism of human manganese superoxide dismutase. Antioxidants.2018;7:1-16
  10. Guan Y, Hickey MJ, Borgstahl GE, et al. Crystal structure of Y34F mutant human mitochondrial manganese superoxide dismutase and the functional role of tyrosine 34. Biochemistry. 1998;37:4722–30
  11. Mustacich D, Powis G, Thioredoxin reductase. Biochem J. 2000;346:1-8
  12. Witte A-B, Anestål K, Jerremalm E, et al. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med. 2005;39:696-703
  13. Biaglow JE, Miller RA. The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy, Cancer Biology Therapy. 2005;4:13- 20
  14. Fuchs J, Podda M, Packer L. Redox-genome interactions in health and disease. JW Goethe University, Frankfurt, ISBN: 0-203-91287-X. Pub. by, Taylor & Francis, e-library. 2005
  15. Miranda- Vizuete A, Damdimopoulos AE, Spyrou G. The mitochondrial thioredoxin system. Antioxid Redox Signal. 2000;2:801-10
  16. Schafer Fq, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 2000;30:1191-212
  17. Burke-Gaffney A, Callister Me, Nakamura H. Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci. 2005;26:398-404
  18. Matsuo Y, Yodoi J. Extracellular Thioredoxin